

# Thomas C Dowling

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8719787/thomas-c-dowling-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56  
papers

1,718  
citations

21  
h-index

41  
g-index

62  
ext. papers

1,899  
ext. citations

4.1  
avg, IF

4.16  
L-index

#	Paper	IF	Citations
56	Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 607-617	3.5	1
55	Stimulating and sustaining scholarly activity at teaching-intensive institutions. <i>Currents in Pharmacy Teaching and Learning</i> , <b>2021</b> , 13, 228-237	1.5	1
54	Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 397-405	1.7	4
53	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , <b>2019</b> , 6, FSO441	2.7	2
52	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 665-675	4	17
51	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. <i>Translational Research</i> , <b>2018</b> , 195, 25-47	11	18
50	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 624-632.e2	6.9	16
49	Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 390-8	2.9	11
48	Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs". <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 1355-7	3.9	2
47	Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 996-1005	3.9	25
46	Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3491-4	4	0
45	Performance of a divided-load intravenous vancomycin dosing strategy for obese patients. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 861-8	2.9	4
44	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. <i>Surgical Infections</i> , <b>2015</b> , 16, 829-32	2	4
43	A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. <i>American Journal of Nephrology</i> , <b>2014</b> , 39, 543-52	4.6	21
42	Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. <i>Regulatory Toxicology and Pharmacology</i> , <b>2014</b> , 68, 297-303	3.4	22
41	Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. <i>Hepatology</i> , <b>2014</b> , 59, 1532-42	11.2	88
40	Reply to: "Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling". <i>Journal of Hepatology</i> , <b>2013</b> , 58, 842-3	13.4	

39	Evaluation of synchronous versus live instructional delivery methods on student academic outcomes and perceptions at a multi-campus school. <i>Currents in Pharmacy Teaching and Learning</i> , <b>2013</b> , 5, 381-386	1.5	6
38	Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 912-21	5.8	97
37	Impact of medication therapy management on underserved, primarily Hispanic patients with diabetes. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 665-70	2.9	8
36	Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 1611-7	2.9	8
35	Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. <i>Journal of Clinical Pharmacology</i> , <b>2013</b> , 53, 962-6	2.9	11
34	Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. <i>AAPS Journal</i> , <b>2012</b> , 14, 571-80	3.7	16
33	Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1675-83	0.7	13
32	Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 1130-44	5.8	69
31	Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation. <i>Annals of Pharmacotherapy</i> , <b>2011</b> , 45, e44	2.9	11
30	Clinical evaluation of natalizumab for formulary consideration. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 1279-87	5.4	1
29	Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 776-86	5.8	52
28	Drug adsorption efficacy and palatability of a novel charcoal cookie formulation. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 888-94	5.8	2
27	Recommended education for pharmacists as competitive clinical scientists. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 236-44	5.8	29
26	Estimated GFR vs creatinine clearance for drug dosing. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 984-5; author reply 985-6	7.4	8
25	The relationship of oxidative stress and cholesterol with dipping status before and after aerobic exercise training. <i>Blood Pressure</i> , <b>2009</b> , 18, 171-9	1.7	6
24	A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 1-5	3.3	86
23	Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 575-83	6.9	25
22	Disclosure and ethical conduct of clinical research. <i>American Journal of Health-System Pharmacy</i> , <b>2008</b> , 65, 1851-3	2.2	1

21	The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 609-17	3.3	79
20	Differential aerobic exercise-induced changes in plasma aldosterone between African Americans and Caucasians. <i>Experimental Physiology</i> , <b>2007</b> , 92, 871-9	2.4	10
19	Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, S3-7; quiz S23-5	2.2	41
18	Urinary cotinine as an objective measure of cigarette smoking in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 1950-4	4.3	14
17	Role of potassium excretion and percent body fat on ethnic differences in plasma aldosterone levels. <i>Ethnicity and Disease</i> , <b>2006</b> , 16, S4-10-4	1.8	4
16	Determination of Rhodamine 123 in cell lysate by HPLC with visible wavelength detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2005</b> , 814, 259-62	3.2	12
15	Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 1808-12	5.9	59
14	Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 2541-4	2.2	25
13	Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. <i>Circulation</i> , <b>2004</b> , 110, 1620-5	16.7	160
12	Validation of a simplified method for determination of cimetidine in human plasma and urine by liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 799, 337-41	3.2	22
11	Renal interaction between itraconazole and cimetidine. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 919-27.9	2.9	23
10	Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 436-42	5.8	20
9	Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. <i>Journal of Pharmaceutical Sciences</i> , <b>2003</b> , 92, 414-23	3.9	48
8	Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 427-34	6.1	90
7	Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2002</b> , 768, 305-13	3.2	12
6	Drug Metabolism Considerations in Patients With Chronic Kidney Disease. <i>Journal of Pharmacy Practice</i> , <b>2002</b> , 15, 419-427	1.3	2
5	Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , <b>2001</b> , 59, 295-303	9.9	15
4	Determination of famotidine in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , <b>1999</b> , 732, 239-43		33

- |   |   |     |     |
|---|---|-----|-----|
| 3 | Comparison of iothalamate clearance methods for measuring GFR. <i>Pharmacotherapy</i> , <b>1999</b> , 19, 943-50  | 5.8 | 14  |
| 2 | Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , <b>1998</b> , 716, 305-13 |     | 23  |
| 1 | Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. <i>Annals of Internal Medicine</i> , <b>1995</b> , 123, 250-9                         | 8   | 327 |